Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
ISIS Pharmaceuticals, Inc. v. Santaris Pharma A/S Corp. et al
Case Number:
3:11-cv-02214
Court:
Nature of Suit:
Judge:
Firms
-
February 27, 2014
Santaris Can't Skirt Infringement Claim In Isis Patent Row
A California federal judge on Thursday refused to let Santaris Pharma A/S Corp. off the hook in Isis Pharmaceuticals Inc.'s infringement suit accusing Santaris of leveraging Isis' patented drug discovery development platform to sign multimillion-dollar development deals, saying Santaris isn't protected by a safe harbor statute.
-
September 20, 2012
Santaris Can't Skirt Isis Suit Over Drug Development Deals
A California federal judge on Wednesday refused to let Santaris Pharma A/S Corp. off the hook in Isis Pharmaceuticals Inc.'s infringement suit accusing its competitor of leveraging Isis' patented gapmer antisense drug development platform to sign multimillion-dollar deals with industry giants.
-
September 23, 2011
Isis Calls Out Santaris Over Drug Development Deals
Drug developer Isis Pharmaceuticals Inc. slammed Santaris Pharma A/S Corp. with a patent infringement lawsuit Thursday, accusing its competitor of leveraging Isis' patented gapmer antisense drug development platform to sign multimillion-dollar deals with drug industry giants.